In a pilot clinical study examining the safety of preoperative single dose ipilimumab (anti-CTLA-4) and/or cryoablation in 19 women with early-stage breast cancer, not only was the combination safe, favorable intratumoral and systemic immunologic effects were also noted (19). The gene discussed is CTLA4; the disease is breast carcinoma.